These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25824664)

  • 21. [Increase in rate of resistance to fusidic acid among Staphylococcus aureus isolates from patients admitted with atopic dermatitis].
    Peeters KA; Mascini EM; Blok HE; Sanders CJ
    Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2100-1. PubMed ID: 12448968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
    Howden BP; Grayson ML
    Clin Infect Dis; 2006 Feb; 42(3):394-400. PubMed ID: 16392088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in rpoB and fusA cause resistance to rifampicin and fusidic acid in methicillin-resistant Staphylococcus aureus strains from a tertiary hospital in Malaysia.
    Lim KT; Teh CS; Yusof MY; Thong KL
    Trans R Soc Trop Med Hyg; 2014 Feb; 108(2):112-8. PubMed ID: 24336696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel cephalosporin derivatives possessing a substituted cinnamoyl moiety at the 7 beta-position. Synthesis, structural characterization and antibacterial activity of 3-acetoxymethyl cephalosporin derivatives.
    López MA; Rodríguez Z; González M; Tolón B; Avila R; González I; Garmendía L; Mamposo T; Carrasco R; Pellón R; Vélez H; Fini A
    Eur J Med Chem; 2004 Aug; 39(8):657-64. PubMed ID: 15276299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spread of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) in general practice patients in the south of The Netherlands.
    Rijnders MI; Wolffs PF; Hopstaken RM; den Heyer M; Bruggeman CA; Stobberingh EE
    J Antimicrob Chemother; 2012 May; 67(5):1176-80. PubMed ID: 22290345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada.
    Pfaller MA; Castanheira M; Sader HS; Jones RN
    Int J Antimicrob Agents; 2010 Mar; 35(3):282-7. PubMed ID: 20036520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel fusidic acid resistance determinant, fusF, in Staphylococcus cohnii.
    Chen HJ; Hung WC; Lin YT; Tsai JC; Chiu HC; Hsueh PR; Teng LJ
    J Antimicrob Chemother; 2015 Feb; 70(2):416-9. PubMed ID: 25313205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008).
    Castanheira M; Watters AA; Mendes RE; Farrell DJ; Jones RN
    J Antimicrob Chemother; 2010 Jul; 65(7):1353-8. PubMed ID: 20430787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of fusidic acid-resistant Staphylococcus aureus isolates in the community of Casablanca (Morocco).
    Elazhari M; Abu-Quatouseh LF; Elhabchi D; Zerouali K; Dersi N; Saile R; Timinouni M; Becker K
    Int J Med Microbiol; 2012 Mar; 302(2):96-100. PubMed ID: 22197537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenazine antibiotic inspired discovery of potent bromophenazine antibacterial agents against Staphylococcus aureus and Staphylococcus epidermidis.
    Borrero NV; Bai F; Perez C; Duong BQ; Rocca JR; Jin S; Huigens RW
    Org Biomol Chem; 2014 Feb; 12(6):881-6. PubMed ID: 24389824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro synergistic antibacterial activities of helvolic acid on multi-drug resistant Staphylococcus aureus.
    Qin L; Li B; Guan J; Zhang G
    Nat Prod Res; 2009; 23(4):309-18. PubMed ID: 19296371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Predominance of multidrug resistant strains with reduced susceptibility to fusidic acid among methicillin-resistant Staphylococcus aureus strains (MRSA) isolated in the Gdánsk region].
    Wiśniewska K; Piechowicz L; Galiński J
    Pol Merkur Lekarski; 2000 Nov; 9(53):746-50. PubMed ID: 11204320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survey, characterization and susceptibility to fusidic acid of Staphylococcus aureus in the Carmarthen area.
    El-Zimaity D; Kearns AM; Dawson SJ; Price S; Harrison GA
    J Antimicrob Chemother; 2004 Aug; 54(2):441-6. PubMed ID: 15269197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation of 8-hydroxyquinoline derivatives as potential antibiotics against Staphylococcus aureus.
    Lam KH; Gambari R; Lee KK; Chen YX; Kok SH; Wong RS; Lau FY; Cheng CH; Wong WY; Bian ZX; Chan AS; Tang JC; Chui CH
    Bioorg Med Chem Lett; 2014 Jan; 24(1):367-70. PubMed ID: 24269165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility testing and clinical effect of fusidic acid in oxacillin-resistant Staphylococcus aureus infections.
    Liu CP; Lee CM; Su SC; Li YT
    J Microbiol Immunol Infect; 1999 Sep; 32(3):194-8. PubMed ID: 10637718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methicillin- and gentamicin-resistant Staphylococcus aureus: susceptibility to fosfomycin, cefamandole, N-formimidoyl-thienamycin, clindamycin, fusidic acid and vancomycin.
    Graninger W; Leitha T; Breyer S; Francesconi M; Lenz K; Georgopoulos A
    Drugs Exp Clin Res; 1985; 11(1):23-7. PubMed ID: 3869801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activity of novel benzopolycyclic amines.
    Barniol-Xicota M; Escandell A; Valverde E; Julián E; Torrents E; Vázquez S
    Bioorg Med Chem; 2015 Jan; 23(2):290-6. PubMed ID: 25515953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and antibacterial and cytotoxic activities of new N-3 substituted thiazolidine-2,4-dione derivatives bearing the pyrazole moiety.
    Desai NC; Satodiya HM; Kotadiya GM; Vaghani HV
    Arch Pharm (Weinheim); 2014 Jul; 347(7):523-32. PubMed ID: 24729458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integration of multiscale molecular modeling approaches with the design and discovery of fusidic acid derivatives.
    Lu J; Ni JX; Wang JA; Liu ZY; Shang KL; Bi Y
    Future Med Chem; 2019 Jun; 11(12):1427-1442. PubMed ID: 31304828
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.